DRUG PRICING CONTROVERSY
TODAY'S HEADLINES
After protests by patients and Congressional representatives, Mylan is offering discounts on its injectable epinephrine (EpiPen) for severe allergy attacks. Read more |
|
FDA recently granted breakthrough therapy designation for esketamine (Janssen Research & Development), an investigational medication to treat major depressive disorder with imminent risk for suicide. Why it's unique
|
CONTINUING PHARMACY EDUCATION
This month's CE activity, "Interventions to improve quality of life for patients with psoriasis and psoriatic arthritis," is open for pharmacists and pharmacy technicians.
The goal of this activity is to educate pharmacists and pharmacy technicians about pharmacist intervention in improving the quality of life for patients with psoriasis and psoriatic arthritis.
Pharmacists and pharmacy technicians can earn up to 2 hours of CPE credit for completing this knowledge-based activity from the University of Connecticut School of Pharmacy and Drug Topics. More
|
EDITOR'S PICK
Soon after FDA granted priority review and breakthrough therapy designation to Gilead's Epclusa, a combination drug for hepatitis C, the agency approved AbbVie's new combination drug to treat the disease. Read more
|
|
|
